Do I Need a Prescription for Psychedelic Treatment or Services?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Anyone who has heard about legal psilocybin services in Oregon or Colorado, or about ketamine clinics, and wants to know whether a doctor’s prescription or diagnosis is required before they can access these options.

The short answer

It depends entirely on which substance and which access pathway you are asking about. For Oregon and Colorado’s licensed psilocybin programs, no prescription is required. For ketamine, a prescription from a licensed physician is required. For MDMA, no legal treatment pathway currently exists in the United States outside of clinical trials. For clinical trials, enrollment criteria — not prescriptions — determine access. Understanding which category your question falls into is the first step toward a useful answer.

Oregon psilocybin services: no prescription required

Oregon’s licensed psilocybin program does not require a prescription, a medical referral, or a clinical diagnosis. Any adult 21 or older can access services directly by contacting a licensed service center and completing a preparation session with a licensed facilitator. The facilitator conducts an intake assessment to screen for contraindications — factors that may make a session unsafe — but that assessment is not a diagnostic evaluation and does not require a physician’s involvement.

This is a deliberate feature of Oregon’s regulatory design. Measure 109 established psilocybin services as a health and wellness option, not as a medical treatment requiring a diagnosed condition. The absence of a prescription requirement reflects the legislature’s intent to create a non-medical access pathway.

The facilitation relationship in Oregon is also explicitly not a clinical relationship. A facilitator who does not hold a separate clinical license is not providing treatment. Even facilitators who hold separate healthcare credentials and operate under Oregon’s dual licensure framework introduced by HB 2387 are providing psilocybin services under their facilitator license — a distinct role with its own scope, not an extension of their clinical license into a prescription-based model.

Colorado natural medicine services: no prescription required

Colorado’s licensed program similarly requires no prescription, no referral, and no diagnosis. Adults 21 and older can access natural medicine services at a licensed healing center by completing an initial consultation and screening assessment with a licensed facilitator. The facilitator may require clearance from the participant’s treating provider if the participant has certain medical conditions — cardiovascular disease, uncontrolled hypertension, liver disease, seizure disorders, or severe chronic illness — but that clearance is a safety measure, not a prescription authorizing the service.

Like Oregon, Colorado frames its program as a health and wellness access model, not a prescription drug program.

Ketamine: prescription required

Ketamine is different. It is a Schedule III controlled substance under the federal Controlled Substances Act, and it is FDA-approved as an anesthetic. Physicians may prescribe ketamine off-label for conditions including treatment-resistant depression and PTSD, and ketamine infusion clinics operate throughout the United States under this off-label prescribing authority. Esketamine, sold as Spravato, is FDA-approved specifically for treatment-resistant depression and major depressive disorder with acute suicidal ideation, and is administered under a federal Risk Evaluation and Mitigation Strategy (REMS) in certified clinical settings.

Accessing ketamine therapy requires a licensed physician to prescribe it. That prescription reflects ketamine’s status as a controlled substance with accepted medical use — the legal and regulatory framework that makes physician-authorized treatment possible. Psilocybin’s Schedule I status, which defines it as having no accepted medical use, is precisely why no analogous prescription pathway exists for it at the federal level.

MDMA: no legal treatment pathway outside clinical trials

MDMA is a Schedule I controlled substance. The FDA issued a Complete Response Letter in August 2024 declining to approve MDMA-assisted therapy for PTSD. As of early 2026, there is no FDA-approved MDMA treatment, no prescription pathway for MDMA therapy, and no state licensed program for MDMA. The only legal way to receive MDMA in a therapeutic context in the United States is through an authorized clinical trial. Enrollment in a clinical trial is governed by trial-specific eligibility criteria, not by a prescription.

Clinical trials: eligibility criteria, not prescriptions

Clinical trials for psilocybin, MDMA, and other psychedelics do not operate through the prescription model. Entry is determined by a trial’s inclusion and exclusion criteria — specific conditions the protocol is designed to study, health history requirements, medication restrictions, and other factors determined by the trial’s design. A physician or researcher administers the substance within the trial’s authorized protocol, but that administration is not prescribing in the conventional sense.

Clinical trial participation is a research relationship, not a treatment relationship. Participants receive investigational drugs under IRB-approved protocols. They are not patients receiving prescribed medications.

The prescription question as a category error

When someone asks whether they need a prescription for psilocybin services, they are often importing an assumption from the conventional healthcare model — that access to any substance with therapeutic effects requires a physician to authorize it. In Oregon and Colorado, that assumption does not apply. The access pathway runs through a licensed facilitator and a licensed service center, not through a physician and a pharmacy.

This distinction has practical consequences. It means a person who has not been diagnosed with any condition can access Oregon or Colorado psilocybin services. It means a person whose physician has never heard of psilocybin therapy, or who declines to recommend it, is not blocked from access. It also means the facilitation relationship carries different duties, protections, and accountability structures than a prescription-based treatment relationship — a distinction that matters if something goes wrong.

What could change this

If psilocybin is ever rescheduled from Schedule I to Schedule II under the federal Controlled Substances Act, a prescription pathway analogous to ketamine’s could potentially become available. Schedule II substances — like oxycodone, Adderall, and fentanyl — have accepted medical uses and can be prescribed by licensed physicians. Rescheduling would not automatically create a prescription pathway, but it would remove the legal barrier that currently makes one impossible at the federal level.

New Mexico’s Medical Psilocybin Act, signed in April 2025, takes a different approach than Oregon and Colorado: it creates a state-regulated medical psilocybin program that requires a qualifying diagnosis — treatment-resistant depression, PTSD, substance use disorders, or end-of-life care — and oversight by a licensed healthcare provider. New Mexico’s program is designed as a medical model, which means access is tied to clinical criteria rather than simply age and consent. That program was still in its implementation phase as of early 2026.

Common mistakes and misconceptions

“I need my doctor to refer me to a psilocybin session.” In Oregon and Colorado, no referral is required. You can contact a licensed service center directly.

“If my doctor prescribes psilocybin, I can get it at a pharmacy.” No prescription pathway for psilocybin exists at the federal level. A physician cannot prescribe a Schedule I substance. Oregon and Colorado’s programs operate outside the prescription model entirely.

“Ketamine clinics work the same way as psilocybin service centers.” They do not. Ketamine is Schedule III with accepted medical use and FDA approval as an anesthetic, which is why a prescription-based treatment pathway exists for it. Psilocybin’s Schedule I status puts it in a fundamentally different legal category.

“If psilocybin is a health and wellness service, my insurance will cover it.” Oregon and Colorado’s programs are not covered by health insurance. Coverage requires federal regulatory recognition of a substance as having accepted medical use. Psilocybin’s Schedule I status and the programs’ non-medical framing both preclude insurance reimbursement under current law.

When you should speak with a lawyer

You should speak with a lawyer if:

You are a licensed healthcare provider who has been asked by a patient about accessing psilocybin services and you want to understand your scope of practice obligations in that conversation
You are building a business that positions itself at the intersection of the prescription model and the licensed facilitation model and want to confirm which legal framework governs your activities
You are in New Mexico and want to understand how that state’s medical psilocybin model’s eligibility requirements apply to your specific situation

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.